Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT).

Gampenrieder, SP; Dezentje, V; Lambertini, M; de Nonneville, A; Marhold, M; Le Du, F; Serrano, CS; Costa, DA; Blondeaux, E; Del Mastro, L; Bertucci, F; Goncal-ves, A; Bartsch, R; Deleuze, A; Salgado, AC; Vitorino, M; Tinchon, C; Pecen, L; Rinnerthaler, G; Greil, R. ANN ONCOL. 2022; 33: S208-S208.

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict re-sistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Gampenrieder, SP; Steiner, M; Hufnagl, C; Hackl, H; Rinnerthaler, G; Westphal, T; Huemer, F; Monzo-Fuentes, C; Morre, P; Hauser-Kronberger, C; Greil, R. ANN ONCOL. 2022; 33: S141-S141.

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

von der Heyde, E; Burkle, D; Forstbauer, H; Hubner, G; Schmidt, B; Schroder, J; Distelrath, A; Wierecky, J; Stubs, P; Kisro, J; Welslau, M; Muller-Huesmann, H; Gohler, T; Krammer-Steiner, B; Schwaner, I; Hering-Schubert, C; Gerger, A; Greil, R; Jacobasch, L; Reichenbach, F; Stintzing, S; Prager, G. ANN ONCOL. 2022; 33: S248-S248.

Updated Results of Tucatinib versus Placebo in Combination with Trastuzu-mab and Capecitabine in Patients with pretreated metastatic HER2-positive Breast Cancer with CNS Metastases (HER2CLIMB).

Greil, R; Lin, UN; Murthy, KR; Abramson, V; Anders, C; Bachelot, T; Bedard, LP; Borges, V; Cameron, D; Carey, L; Chien, JA; Curigliano, G; DiGiovanna, PM; Gel-mon, K; Hortobagyi, G; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Oliveira, M; Paplomata, E; Pegram, M; Slamon, D; Zelnak, A; Ramos, J; Feng, W; Winer, E. Geburtshilfe Frauenheilkd 2022; 82(04): e4-e5. DOI: 10.1055/s-0042-1746156

REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) plus en-docrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis.

Singer, CF; Egle, D; Greil, R; Petru, E; Ohler, L; Balic, M; Tinchon, C; Pfeiler, G; Marhold, M; Brunner, C; Haider, K; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Uthman, S; Mraz, B; Bartsch, R. ANN ONCOL. 2022; 33: S217-S217.

Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubi-cin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previ-ously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study.

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Her-baux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Miguel, J; Burgues, B; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Abrisqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, C; Salles, G; Collins, G. BRIT J HAEMATOL. 2022; 197: 14-16.

Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

Aggarwal, RR; Rottey, S; Aparicio, A; Greil, R; Reimers, MA; Sandhu, SK; Zhang, YR; Salvati, M; Sadraei, NH. J CLIN ONCOL. 2022; 40(6): DOI: 10.1200/JCO.2022.40.6_suppl.TPS197 Journal of Clinical Oncology 40, no. 6_suppl

Detecting Bacterial-Human Lateral Gene Transfer in Chronic Lymphocy-tic Leukemia.

Akimova, E; Gassner, FJ; Greil, R; Zaborsky, N; Geisberger, R. Int J Mol Sci. 2022 Jan 20;23(3):1094. doi: 10.3390/ijms23031094.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Bishop, MR; Dickinson, M; Purtill, D; Barba, P; Santoro, A; Hamad, N; Kato, K; Sureda, A; Greil, R; Thieblemont, C; Morschhauser, F; Janz, M; Flinn, I; Rabitsch, W; Kwong, YL; Kersten, MJ; Minnema, MC; Holte, H; Chan, EHL; Martinez-Lopez, J; Muller, AMS; Maziarz, RT; McGuirk, JP; Bachy, E; Le Gouill, S; Dreyling, M; Harigae, H; Bond, D; Andreadis, C; McSweeney, P; Kharfan-Dabaja, M; Newsome, S; Degtyarev, E; Awasthi, R; del Corral, C; Andreola, G; Masood, A; Schuster, SJ; Jager, U; Borchmann, P; Westin, JR. N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.

Bartsch, R; Gampenrieder, SP; Rinnerthaler, G; Petru, E; Egle, D; Petzer, A; Balic, M; Pluschnig, U; Sliwa, T; Singer, C. Wien Klin Wochenschr. 2022 Jan;134(1-2):63-72. doi: 10.1007/s00508-021-01987-9. Epub 2022 Jan 28.